

Technology: [Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction](#)

VA ID Number: 10-161

Inventor: Arthur Vandenkark

Location: Portland, OR

Topic: Genomics

USPTO Issue Date: 6/7/16

Patent Number: 9,359,425

This patent was assigned by the VA.

Contact

Lee Sylvers, PhD

lee.sylvers@va.gov

202-443-5646

Abstract

Methods are provided for the treatment of subjects with cognitive or neuropsychiatric impairment induced by substance addiction and for increasing cognitive function in a subject with substance addiction. In some embodiments, the methods include administering to the subject a therapeutically effective amount of a major histocompatibility complex (MHC) molecule including covalently linked first, second, and third domains; wherein the first domain is an MHC class II .beta.1 domain and the second domain is an MHC class II .alpha.1 domain; or wherein the first domain is an MHC class I .alpha.1 domain and the second domain is an MHC class I .alpha.2 domain; and wherein the third domain is covalently linked to the first domain and comprises an antigen of the central or peripheral nervous system.